-
LIV cash crunch hits Asian Tour as Korea Open prize money cut
-
'Wiped out': Ukraine's bird lovers long for peaceful skies
-
Union calls strike at South Korea chip giant Samsung Electronics
-
Putin, Xi hail 'unyielding' ties in talks after Trump visit
-
Director Boots Riley says new film 'I Love Boosters' is an 'optimistic' satire
-
Sky bridges, citizen science protect endangered Malaysia monkeys
-
Elephant in the room: Nepal's first Cannes film takes on taboos
-
Pentagon says it has reduced brigades in Europe from four to three
-
Union calls strike at S. Korea chip giant Samsung Electronics
-
Knicks rally from 22 points down to stun Cavs in NBA East finals opener
-
Eala and Tjen bring a Southeast Asian 'sense of pride' to Roland Garros
-
Djokovic trying to hold back time at French Open
-
How are the World Cup favourites shaping up?
-
Taiwan leader says 'foreign forces' cannot decide island's future
-
Knicks rally to stun Cavs in overtime in NBA Eastern Conference finals opener
-
Pressure mounts at United Nations for climate change 'lifeline'
-
Cubans want change, but not at gunpoint
-
Asia stocks slide on inflation fears as yields surge
-
Putin, Xi to underscore alliance strength after Trump visit
-
Help wanted: Australian conservation group seeks new koala rescue dog
-
Musk's empire as SpaceX counts down to Wall Street liftoff
-
SpaceX's IPO moonshot draws some doubters on Wall Street
-
Under Trump pressure, EU agrees to implement US trade pact
-
Republican who stood up to Trump defeated in Kentucky primary
-
Acting US attorney general defends fund for prosecuted Trump allies
-
Mavericks part ways with head coach Kidd
-
Shock and bafflement at San Diego mosque where three were killed
-
US enforces law to crack down on sexual deepfakes
-
Arsenal crowned Premier League champions after Man City draw
-
New York art auctions roar back with blockbuster sales
-
US says held talks with Cuba on $100 mln offer
-
Chelsea beat Spurs to leave rivals in 'embarrassing' relegation danger
-
Google wants its search bar to act on your behalf in AI revamp
-
Taiwan author wins International Booker for 'slyly sophisticated' novel
-
Iran 'very confident' about World Cup protocols: federation vice-president
-
Google unveils smart glasses, taking on Meta
-
Guardiola swerves Man City exit talk as title hopes ended
-
Chiefs' Rice jailed for probation violation
-
Five factors in Arsenal's Premier League title triumph
-
Mikel Arteta: Pep protege to Premier League winner
-
How Arsenal banished 'nearly men' tag to end 22-year title wait
-
Arsenal win Premier League after Man City held by Bournemouth
-
From graduation boos to voter unease: AI anxiety grows in the US
-
Lost in Trump's climate boast: best-case scenario abandoned
-
Hantavirus cruise operator says ship not source of outbreak
-
Trump shows off ballroom site with 'drone empire' planned for roof
-
Rubio to attend NATO talks, pay first visit to India
-
Under Trump pressure, EU seeks deal to end trade standoff
-
Airbus seeks to cut peripheral expenses due to Mideast war
-
France encourages women to report rape in probes of star Bruel
Japan biochemist who discovered statins, Akira Endo, dies
Japanese biochemist Akira Endo, who discovered cholesterol-lowering statins, has died aged 90, his former student and colleague said on Tuesday.
Statins, which can prevent heart attacks or strokes, are among the most commonly prescribed drugs worldwide.
Keiji Hasumi, a professor who was a long-time associate of Endo, said the scientist had died on June 5.
"His work was truly great. Statins didn't exist before Endo," Hasumi told AFP. "It has the same value and impact as the discovery of penicillin."
Johns Hopkins Medicine says more than 200 million people take statins. Studies say the global market for them was worth $15 billion in 2023 and is expected to grow.
Endo experimented on thousands of microbes to reach his 1973 discovery of mevastatin -- an agent derived from penicillin that reduces so-called "bad" cholesterol in the blood.
The researcher "was a tough, strict person. He was insightful and perceptive," and "able to see the hidden essence of things", Hasumi said.
Endo was born in 1933 to a farming family in rural northern Japan.
His ambitions began early thanks to his grandfather, who was interested in medicine and became a "great home teacher", Endo said in a 2008 autobiographical essay.
As a student, Endo became interested in antibiotics like penicillin, "deeply impressed" by how many lives they had saved, his essay in the journal Nature Medicine said.
Endo carried out research in New York in the late 1960s, when coronary heart disease was the main cause of US deaths.
"I often saw ambulances coming to take elderly people who had suffered a heart attack to hospital", which "made me realise the importance of developing a cholesterol-lowering drug", he said.
Endo worked at the Tokyo University of Agriculture and Technology, which issued a statement expressing condolences over his death, and at Japanese drugmaker Sankyo, now a part of Daiichi-Sankyo.
He spent two years testing 6,000 strains of microbe in the search for a new drug that could help achieve his goal before finally finding mevastatin.
Conflicting reports on the benefits and potential harms of statins in recent years have prompted some people prescribed the drugs to stop taking them.
"Are statins safe? For most people, the answer is a resounding yes, according to a 2014 Johns Hopkins meta-analysis of 20 years worth of published research," the US university says.
Endo was a strong candidate for a Nobel Prize, but never won. In a report on his death, Japanese broadcaster NHK noted Endo had received other accolades, including being honoured as a Person of Cultural Merit by the government in 2011.
His discovery "was the result of many twists and turns", Hasumi said.
"He reached his goal by overcoming so many challenges, without which medicines cannot be created, I think I remember him saying."
K.Hassan--SF-PST